natgillin/translations-raw huggingface dataset:
The uptake of glucose from blood into peripheral muscle and fat tissues occurs via a special transport proteins, located in the cells membrane. 
Prenos glukoze iz krvi v periferna mišična in maščobna tkiva poteka preko posebnih transportnih proteinov, ki se nahajajo v membrani celic.
The transport of glucose in these tissues is the rate limiting step in the use of glucose. 
Transport glukoze v ta tkiva je stopnja, ki omejuje hitrost uporabe glukoze.
Maximum serum concentrations (Cmax) are reached approximately 2.5 hours after oral intake (mean 0.3 µg/mL during multiple dosing of 4 mg daily). 
Maksimalne koncentracije v serumu (Cmax) so dosežene približno 2,5 uri po peroralnem jemanju (v povprečju 0,3 µg/ml med večkratnim odmerjanjem po 4 mg dnevno).
Start the administration of glucose as soon as possible, if necessary by a bolus intravenous injection of 50 ml of a 50% solution, followed by an infusion of a 10% solution with strict monitoring of blood glucose. 
Takoj, ko je mogoče začnite z dajanjem glukoze, po potrebi z intravensko bolusno injekcijo 50 ml 50% raztopine, ki ji sledi infuzija 10% raztopine s skrbnim spremljanjem glukoze v krvi.
The tablets are supplied in aluminium/aluminium blister packs containing either 14, 28, 30, 50, 90 or 98 tablets. 
Tablete so na voljo v aluminij/aluminij pretisnih omotih, ki vsebujejo bodisi 14, 28, 30, 50, 90 ali 98 tablet.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, p=0.029). 
O primerih raka mehurja, so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12.506 bolnikov, 0,15%) kot v kontrolnih skupinah (7 primerov od 10.212 bolnikov, 0,07%) HR = 2,64 (95% IZ 1,11-6,31, p = 0,029).
If patients report hypoglycaemia, the dose of Tandemact should be reduced or free combination therapy should be considered. 
Če bolniki poročajo o hipoglikemiji, je treba odmerek zdravila Tandemact znižati ali razmisliti o kombinacijski terapiji.
Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6). 
Zato se morajo tveganja za zanositev zavedati, in če bolnica želi zanositi ali če zanosi, je treba zdravljenje prekiniti (glejte poglavje 4.6).
Tandemact may either increase or weaken the effects of the following medicines: - coumarin derivatives such as warfarin (to slow down or stop blood clotting) 
Zdravilo Tandemact lahko bodisi poveča ali zmanjša učinek naslednjih zdravil: - derivati kumarina, kot je varfarin (za upočasnitev ali ustavitev strjevanja krvi)
Animal studies have shown reproductive toxicity which was most likely related to the pharmacological action (hypoglycaemia) of glimepiride. 
Študije na živalih so pokazale reproduktivno toksičnost, ki je bila najverjetneje povezana s farmakološkim delovanjem (hipoglikemija) glimepirida.
After a single dose of radiolabelled glimepiride, 58% of the radioactivity was recovered in the urine, and 35% in the faeces. 
Po enkratnem odmerku radioaktivno označenega glimepirida, se je 58% radioktivnosti izločilo v urinu in 35% v blatu.
Linearity/non-linearity Single dose studies demonstrate linearity of pharmacokinetics in the therapeutic dose range. 
Linearnost/nelinearnost Študije z enkratnimi odmerki kažejo linearnost farmakokinetike v terapevtskem razponu odmerkov.
Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected. 
Interakcij s snovmi, ki jih presnavljajo ti encimi, npr. s peroralnimi kontraceptivi, ciklosporinom, zaviralci kalcijevih kanalčkov in inhibitorji HMGCoA reduktaze, ni pričakovati.
There are no adequate data from the use of pioglitazone in pregnant women. 
Ni zadostnih podatkov o uporabi pioglitazona pri nosečnicah.
If ALT levels are increased to 3 x upper limit of normal during Tandemact therapy, liver enzyme levels should be reassessed as soon as possible. 
Če se med zdravljenjem z zdravilom Tandemact ravni ALT zvišajo do 3-kratne zgornje meje normalnih vrednosti, je treba ravni jetrnih encimov čim prej ponovno kontrolirati.
4 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic medicinal products. 
4 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri drugih hipoglikemičnih zdravilih.
Risk related to pioglitazone 
Tveganje, povezano s pioglitazonom
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. 
Izračunana incidenca zlomov je bila 1,9 zlomov na 100 bolnikovih let pri ženskah, zdravljenih s pioglitazonom in 1,1 zlom na 100 bolnikovih let pri ženskah, zdravljenih s primerjalnim zdravilom.
Tandemact should not be used in patients with severe renal function disorders (creatinine clearance < 30 ml/min, see section 4.3). 
Zdravila Tandemact se ne sme uporabljati pri bolnikih s hudo motnjo ledvičnega delovanja (očistek kreatinina < 30 ml/min, glejte poglavje 4.3).
Blood and lymphatic system disorders changes in haematology1 
Bolezni krvi in limfatičnega sistema hematološke spremembe1
In patients with low creatinine clearance, there was a tendency for glimepiride clearance to increase and for average serum concentrations to decrease, most probably resulting from a more rapid elimination because of lower protein binding. 
Pri bolnikih z nizkim očistkom keratina, je bila tendenca, da se očistek glimepirida poveča in povprečne serumske koncentracije zmanjšajo, kar verjetno izhaja iz hitrejšega izločanja zaradi manjše vezave na beljakovine.
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. 
Ko so izločili bolnike, ki so bili v času diagnoze rak mehurja, preiskovanemu zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06%) raka mehurja pri pioglitazonu in 2 primera (0,02%) v kontrolnih skupinah.
Extrapancreatic activity 
Ekstrapankreatično delovanje
In animal fertility studies with pioglitazone, there was no effect on copulation, impregnation or fertility index. 
V študijah plodnosti s pioglitazionom na živalih, niso opazili vpliva na indeks kopulacije, impregnacije ali plodnosti.
In addition, glimepiride seems to have pronounced extrapancreatic effects also postulated for other sulphonylureas. 
Poleg tega kaže, da ima glimepirid izrazite ekstrapankreatične učinke, ki jih imajo domnevno tudi druge sulfonilsečnine.
This finding is based on conventional safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and reproduction toxicity studies. 
To je bilo ugotovljeno na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, rakotvornosti in reproduktivne toksičnosti.
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose of pioglitazone and increase the dose gradually. 
Pri zdravljenju bolnikov z vsaj enim dejavnikom tveganja za razvoj kongestivnega srčnega popuščanja (tj. pred miokardnim infarktom ali simptomatsko boleznijo koronarnih arterij ali v primeru starejših bolnikov), mora zdravnik začeti z najnižjim možnim odmerkom pioglitazona in ga postopoma zviševati.
There is a linear relationship between dose and both Cmax and AUC (area under the time/concentration curve). 
Med odmerkom ter Cmax in AUC obstaja linearna povezanost (površina pod krivuljo koncentracije zdravila in časa).
The decision whether to continue the patient on therapy with Tandemact should be guided by clinical judgement pending laboratory evaluations. 
Odločitev o tem, ali zdravljenje bolnika z zdravilom Tandemact nadaljevati, naj do laboratorijskih vrednotenj temelji na klinični presoji.
Tandemact with alcohol 
Zdravilo Tandemact skupaj z alkoholom
The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia from glimepiride or, for example, as a result of visual impairment. 
Bolnikova zmožnost koncentracije in reagiranja se lahko poslabša zaradi hipoglikemije ali hiperglikemije povezane z glimepiridom, pa tudi npr. zaradi prizadetosti vida.
Hypoglycaemic reactions mostly occur immediately due to the sulphonylurea component of Tandemact. 
Hipoglikemične reakcije se največkrat pojavijo takoj zaradi sulfonilsečnine, ki je sestavina zdravila Tandemact.
Not known (frequency can not be estimated from the available data) - increase in liver enzymes - itchy skin - raised and itchy rash (hives) 
Neznani (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) - povišanje jetrnih encimov - srbečica kože - izbočen in srbeč izpuščaj (koprivnica)
If you have the impression that the effect of Tandemact is too weak, talk to your doctor. 
Če menite, da je učinek zdravila Tandemact prešibak, se posvetujte z zdravnikom.
NAME OF THE MARKETING AUTHORISATION HOLDER Takeda (logo) 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Takeda (logo)
What Tandemact is and what it is used for What you need to know before you take Tandemact How to take Tandemact 
Kaj je zdravilo Tandemact in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Tandemact Kako jemati zdravilo Tandemact Možni neželeni učinki
Passage of the blood brain barrier is low. 
Prehajanje preko krvno-možganske pregrade je počasno.
Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to haemolytic anaemia. 
Zdravljenje bolnikov s pomanjkanjem G6PD z derivati sulfonilsečnine, lahko povzroči hemolitično anemijo.
Treatment with Tandemact therefore requires regular haematological monitoring (especially leucocytes and platelets). 
Zato je pri zdravljenju z zdravilom Tandemact potrebno redno hematološko spremljanje (predvsem levkocitov in trombocitov).
After oral administration of glimepiride, the terminal half-lives of those metabolites were 3 to 6 and 5 to 6 hours respectively. 
Po peroralni uporabi glimepirida je bil razpolovni čas teh presnovkov od 3 do 6 ur in od 5 do 6 ur.
If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. 
Če ste vzeli večji odmerek zdravila Tandemact, kot bi smeli Če po nesreči zaužijete preveč tablet ali če kdo drug ali otrok zaužije vaša zdravila, o tem nemudoma obvestite svojega zdravnika ali farmacevta.
Decrease in blood platelets (which increases risk of bleeding or bruising), red blood cells (which makes the skin pale and cause weakness or breathlessness) and white blood cells(which makes infections more likely) have been reported in patients taking Tandemact rarely (may affect up to 1 in 1,000 people). 
O zmanjšanju števila trombocitov (kar poveča tveganje za krvavitve ali modrice), rdečih krvnih telesc (zaradi česar je koža bleda in pojavi se šibkost ali zasoplost) in belih krvnih telesc (zaradi česar se poveča verjetnost okužb), so poročali redko (pri največ 1 od 1.000 bolnikov) pri bolnikih, ki jemljejo zdravilo Tandemact.
If you forget to take Tandemact 
Če ste pozabili vzeti zdravilo Tandemact
Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). 
Obvestite svojega zdravnika kakor hitro je mogoče, če imate znake srčnega popuščanja, kot so nenavadno težko dihanje ali hitro povečanje telesne mase ali lokalizirano oteklino (edem).
The extrapancreatic effects are for example an improvement of the sensitivity of the peripheral tissue for insulin and a decrease of the insulin uptake by the liver. 
Med ekstrapankreatičnimi učinki so, na primer, izboljšanje občutljivosti za insulin v perifernih tkivih in zmanjšanje jetrnega privzema insulina.
In the 3.5 year PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
V 3,5 letni PROactive študiji je 44/870 (5,1%; 1,0 zlomov na 100 bolniko-let) žensk, zdravljenih s pioglitazonom imelo zlome, v primerjavi s 23/905 (2,5%; 0,5 zlomov na 100 bolnikov-let) žensk, zdravljenih s primerjalnim zdravilom.
This leads to insulin release through exocytosis. 
To povzroči sprostitev insulina z eksocitozo.
The effect of glimepiride is dose-dependent and reproducible. 
Učinek glimepirida je odvisen od odmerka in je ponovljiv.
Glimepiride may either potentiate or weaken the effects of coumarin derivatives. 
Glimepirid lahko poveča ali zmanjša učinek kumarinskih derivatov.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included in insulin. 
V študiji izida pri bolnikih z obstoječo težjo makrovaskularno boleznijo je bila incidenca resnega srčnega popuščanja 1,6% višja pri pioglitazonu kot pri placebu, ko je bil slednji dodan zdravljenju, ki je zajemalo insulin.
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group. 
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45%, v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini, zdravljeni s pioglitazonom.
If you stop taking Tandemact 
Če ste prenehali jemati zdravilo Tandemact
Insulin release 
Izločanje insulina
To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. 
Da bi bolniki ustrezali kriterijem, so morali imeti v anamnezi eno ali več od naslednjega: miokardni infarkt, kap, perkutano srčno intervencijo ali premostitveno operacijo koronarnih arterij, akutni koronarni sindrom, koronarno arterijsko bolezen ali periferno arterijsko obstrukcijsko bolezen.
Take care if you experience abnormal vision. 
Bodite pozorni če imate motnje vida.
Tandemact contains pioglitazone and glimepiride which are anti-diabetic medicines, used to control blood sugar level. 
Zdravilo Tandemact vsebuje pioglitazon in glimepirid, ki sta zdravili za zdravljenje sladkorne bolezni in se uporabljata za nadzor ravni sladkorja v krvi.
In some cases weight increase may be a symptom of cardiac failure therefore weight should be closely monitored. 
V nekaterih primerih je lahko povišanje telesne mase posledica srčne odpovedi, zato je treba telesno maso skrbno spremljati.
Mean dominant serum half-life, which is of relevance for the serum concentrations under multiple-dose conditions, is about 5 to 8 hours. 
Povprečni razpolovni čas dominantnega seruma je približno 5 do 8 ur, kar je pomembno za serumske koncentracije pod pogoji večkratnega odmerjanja.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs; ATC code: A10BD06. 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD06
common uncommon macular oedema not known not known 
pogosti občasni makularni edem neznana neznana
Avoid alcohol while taking Tandemact since alcohol may increase or decrease the blood sugar lowering action of Tandemact in an unpredictable way. 
Izogibajte se alkoholu, ko jemljete zdravilo Tandemact, ker lahko alkohol poveča ali zmanjša učinek zdravila Tandemact na zniževanje ravni sladkorja v krvi na nepredvidljiv način.
Sulphonylurea-derivatives like glimepiride pass into the breast milk. 
Derivati sulfonilsečnin, kot je glimepirid, se izločajo v materino mleko.
Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness. 
Znotraj organskih sistemov so neželeni učinki navedeni po padajoči pogostnosti, ki ji sledi padajoča resnost.
Symptoms may not be present for up to 24 hours after ingestion. 
Simptomi se lahko pojavijo z zamikom do 24 ur po zaužitju.
If you are following a special diet for diabetes, you should continue with this while you are taking Tandemact. 
Če ste na posebni dieti za sladkorno bolezen, z dieto med jemanjem zdravila Tandemact nadaljujte.
The hypoglycaemia may in general be accompanied by neurological symptoms like restlessness, tremor, visual disturbances, coordination problems, sleepiness, coma and convulsions. 
Hipoglikemijo lahko spremljajo nevrološki simptomi kot so nemir, tremor, motnje vida, težave s koordinacijo, zaspanost, koma in konvulzije.
The European Medicines Agency has waived the obligation to submit the results of studies with Tandemact in all subsets of the paediatric population in type 2 diabetes mellitus. 
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Tandemact za vse podskupine pediatrične populacije s sladkorno boleznijo tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Clinical trials have been conducted with co-administered pioglitazone and glimepiride (see section 5.1). 
Klinične študije so opravili s sočasno uporabo pioglitazona in glimepirida (glejte poglavje 5.1).
Following initiation of therapy with Tandemact, it is recommended that liver enzymes be monitored periodically based on clinical judgement. 
Po uvedbi zdravljenja z zdravilom Tandemact je priporočeno, da jetrne encime spremljate redno po klinični presoji.
Investigations weight increased9 
Preiskave povečanje telesne mase9
The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use. 
Opazovano povečano tveganje za zlom pri ženskah v tej skupini podatkov na pioglitazonu je torej 0,8 zlomov na 100 bolnikovih let uporabe.
Musculoskeletal and connective tissue disorders bone fracture7 
Bolezni mišično-skeletnega sistema in vezivnega tkiva zlom kosti7
Nausea, vomiting and epigastric pain may occur. 
Lahko se pojavijo navzea, bruhanje in epigastrične bolečine.
common common common increased lactic dehydrogenase uncommon decrease in sodium serum concentrations very rare very rare alanine aminotransferase increase10 
pogosti pogosti pogosti povišana vrednost laktatne dehidrogenaze občasni znižanje koncentracije natrija v serumu zelo redki zelo redki povišana vrednost alanin aminotransferaze10
Other reactions such as bone fracture, weight increase and oedema may occur commonly (≥ 1/100 to < 1/10) (see section 4.4). 
Druge reakcije, kot so zlomi kosti, povečanje telesne mase in edem se lahko pojavijo pogosto (≥ 1/100 do < 1/10) (glejte poglavje 4.4).
If you stop using Tandemact, your blood sugar may go up. 
Če ste prenehali jemati zdravilo Tandemact, se lahko raven sladkorja v krvi dvigne.
Closing the potassium channel induces depolarisation of the beta cell and results - by opening of calcium channels - in an increased influx of calcium into the cell. 
Zaprtje kalijevih kanalčkov povzroči depolarizacijo celic beta in z odprtjem kalcijevih kanalčkov poveča dotok kalcija v celice.
The following statements reflect the information available on the individual active substances (pioglitazone and glimepiride). 
Naslednje navedbe odražajo dostopne podatke o posameznih učinkovinah (pioglitazonu in glimepiridu).
7 A pooled analysis was conducted of adverse event reports of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8,100 patients in the pioglitazone-treated groups and 7,400 in the comparator-treated groups of up to 3.5 years duration. 
7 Opravljena je bila skupna analiza neželenih učinkov zlomov kosti iz randomiziranih, s primerjalnim zdravilom kontroliranih, dvojno slepih kliničnih preskušanj pri več kot 8100 bolnikov v skupini, zdravljeni s pioglitazonom in 7.400 v skupini, zdravljeni s primerjalnim zdravilom, ki so trajale do 3,5 let.
During therapy with pioglitazone there was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction), consistent with haemodilution. 
Med zdravljenjem s pioglitazonom se je pojavljalo majhno znižanje povprečne vrednosti hemoglobina (4% relativno znižanje) in hematokrita (4,1% relativno znižanje), skladno s hemodilucijo.
Hepatic impairment Tandemact should not be used in patients with hepatic impairment (see section 4.3 and 4.4). 
Okvara jeter Zdravila Tandemact se ne sme uporabljati pri bolnikih z okvaro jeter (glejte poglavje 4.3 in 4.4).
General disorders and administration site conditions oedema8 
Splošne težave in spremembe na mestu aplikacije edem8
Before you start taking Tandemact you will have a blood sample taken to check your liver function. 
Pred začetkom jemanja zdravila Tandemact vam bodo odvzeli vzorec krvi za pregled delovanja jeter.
If you experience symptoms of hypoglycaemia such as cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea, you should take some sugar to increase your blood sugar level again. 
Če izkusite simptome hipoglikemije, kot so hladno znojenje, utrujenost, glavobol, hitro bitje srca, občutek lakote, razdražljivost, živčnost ali siljenje na bruhanje, zaužijte nekaj sladkorja, da znova povečate raven krvnega sladkorja.
If glimepiride is taken simultaneously with certain other medicinal products, both undesired increases and decreases in the hypoglycaemic action of glimepiride can occur. 
Pri sočasnem dajanju glimepirida z nekaterimi drugimi zdravili, lahko pride do neželenega povečanja in zmanjšanja hipoglikemičnega delovanja glimepirida.
H2 antagonists, betablockers, clonidine and reserpine may lead to either potentiation or weakening of the blood glucose lowering effect. 
Zaviralci H2, zaviralci beta, klonidin in reserpin lahko učinek na znižanje glukoze v krvi povečajo ali zmanjšajo.
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. 
Če kak bolnik razvije simptome, ki kažejo na moteno delovanje jeter, kar lahko vključuje nepojasnjeno navzeo, bruhanje, bolečine v trebuhu, utrujenost, anoreksijo in/ali temen urin, je treba kontrolirati jetrne encime.
Tandemact is indicated as second line treatment of adult patients with type 2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride. 
Zdravilo Tandemact je indicirano kot drugi izbor zdravljenja sladkorne bolezni tipa 2 pri odraslih bolnikih, ki kažejo intoleranco za metformin, ali pri bolnikih, pri katerih je metformin kontraindiciran in se že zdravijo s kombinacijo pioglitazona in glimepirida.
There was no significant difference in effect regardless of whether glimepiride was given 30 minutes or immediately before a meal. 
Učinek zdravila se ni pomembno razlikoval, če je bilo uporabljeno 30 minut pred obrokom ali tik pred njim.
In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. 
V kontroliranih kliničnih preskušanjih je bila incidenca poročil o srčnem popuščanju ob zdravljenju s pioglitazonom enaka kot v skupinah zdravljenja s placebom, metforminom in sulfonilsečnino, a se je povišala pri kombiniranem zdravljenju z insulinom.